Top 10 Companies in the (R)-1-Aminoindane (CAS 10277-74-4) Market (2026): Market Leaders Driving Global Pharmaceutical Innovation

MARKET INSIGHTS

The global (R)-1-Aminoindane (CAS 10277-74-4) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(R)-1-Aminoindane is a chiral amine compound derived from indane, characterized by its single stereocenter that confers the (R)-configuration. It serves as a critical chiral building block and pharmaceutical intermediate, widely utilized in the synthesis of enantiomerically pure active pharmaceutical ingredients (APIs). The compound finds notable application in the development of neurological drugs, including selective monoamine oxidase inhibitors (MAOIs), and has been integral to the synthesis of rasagiline, a well-established treatment for Parkinson’s disease.

The market is gaining steady momentum, primarily driven by the rising global burden of neurodegenerative disorders and the pharmaceutical industry’s increasing emphasis on chiral synthesis and stereochemically pure compounds. Furthermore, growing investments in asymmetric synthesis research and the expanding pipeline of CNS-targeted therapeutics are reinforcing demand. Key specialty chemical manufacturers and fine chemical producers, including those operating across North America, Europe, and Asia-Pacific, are actively scaling production capabilities to meet rising pharmaceutical‑grade requirements for this compound.

(R)-1-Aminoindane (CAS 10277-74-4) Market – View in Detailed Research Report

Top 10 Companies in the (R)-1-Aminoindane (CAS 10277-74-4) Market (2026)

1. Hairui Fine Chemicals Co., Ltd. (China)

   Headquarters: Shanghai, China
   Key Offering: Pharmaceutical‑grade (R)-1‑Aminoindane, custom chiral synthesis services

   Hairui has positioned itself as a primary supplier for global API manufacturers, leveraging its in‑house continuous flow hydrogenation platform to deliver enantiomeric excesses above 99.9%. The company’s integration of upstream synthesis with downstream purification reduces lead times and enhances batch consistency, a critical factor for regulators and end users.

   Sustainability & Growth Initiatives:

   • Implementation of solvent‑free catalytic routes to lower CO₂ footprint
   • Investment in renewable energy for plant operations
   • Strategic partnership with a leading U.S. biopharma to co‑develop next‑generation MAO‑B inhibitors

2. Biosynth AG (Switzerland)

   Headquarters: Basel, Switzerland
   Key Offering: High‑purity (R)-1‑Aminoindane, bespoke synthesis for specialty chemicals

   Biosynth’s reputation for cGMP‑compliant production has earned it contracts with several European pharmaceutical giants. Its modular synthesis modules allow rapid scale‑up and accommodate complex chiral architectures, ensuring compliance with stringent ICH guidelines.

   Sustainability & Growth Initiatives:

   • Adoption of biocatalytic resolution to reduce waste streams
   • Launch of a green chemistry advisory service for clients
   • Expansion of capacity in the EU to meet rising demand for CNS therapeutics

3. Capot Chemical Co., Ltd. (China)

   Headquarters: Shenzhen, China
   Key Offering: Research‑grade (R)-1‑Aminoindane, rapid‑delivery API intermediates

   Capot’s focus on high‑throughput synthesis supports R&D labs worldwide. Its streamlined logistics network allows same‑day delivery to key biotech hubs, providing a competitive edge in time‑to‑market for early‑stage projects.

   Sustainability & Growth Initiatives:

   • Implementation of closed‑loop water recycling in production units
   • Collaboration with a Chinese university on asymmetric hydrogenation catalysts
   • Strategic alignment with China’s “Made in China 2025” policy to secure premium contracts

4. Enamine LLC (Ukraine)

   Headquarters: Kyiv, Ukraine
   Key Offering: Technical‑grade (R)-1‑Aminoindane, custom synthesis for academic and industrial partners

   Enamine’s flexible synthesis platform enables rapid prototyping of chiral intermediates, catering to both academic research and commercial development. Its global distribution network ensures reliable supply to North America and Europe.

   Sustainability & Growth Initiatives:

   • Development of low‑energy catalytic processes
   • Investment in digital tracking of batch traceability
   • Partnership with a leading CRO to expand service offerings

5. Achieve Chemicals Ltd. (China)

   Headquarters: Guangzhou, China
   Key Offering: Pharmaceutical‑grade (R)-1‑Aminoindane, scalable production for generics

   Achieve’s focus on cost‑effective scale‑up has made it a preferred supplier for generic manufacturers seeking high‑purity intermediates at competitive prices. Its robust quality assurance framework aligns with global pharmacopeia standards.

   Sustainability & Growth Initiatives:

   • Adoption of green solvent alternatives in purification steps
   • Participation in an industry consortium to standardize chiral purity metrics
   • Expansion of production capacity in the ASEAN region

6. Apollo Scientific Ltd. (UK)

   Headquarters: London, United Kingdom
   Key Offering: Custom chiral synthesis, high‑purity (R)-1‑Aminoindane for specialty chemicals

   Apollo’s expertise in asymmetric catalysis supports the development of next‑generation CNS agents. Its client‑centric approach, offering end‑to‑end synthesis solutions, has attracted several European biopharma firms.

   Sustainability & Growth Initiatives:

   • Investment in renewable energy for its UK facilities
   • Collaboration with a leading academic group on enzyme‑based resolution
   • Launch of a sustainability reporting framework for investors

7. JTD Chemicals Co., Ltd. (China)

   Headquarters: Chengdu, China
   Key Offering: Technical‑grade (R)-1‑Aminoindane, rapid synthesis for research labs

   JTD’s high‑throughput synthesis platform caters to the growing demand for chiral building blocks in academic and industrial settings. Its flexible batch sizing accommodates both small‑scale research and larger commercial projects.

   Sustainability & Growth Initiatives:

   • Implementation of a zero‑waste policy in its production line
   • Partnership with a Chinese biotech cluster to streamline supply chains
   • Investment in AI‑driven process optimization

8. TCI Chemicals (Japan)

   Headquarters: Tokyo, Japan
   Key Offering: Pharmaceutical‑grade (R)-1‑Aminoindane, specialized synthesis for high‑value APIs

   TCI’s focus on precision chemistry and stringent quality control makes it a trusted partner for Japanese and Asian pharmaceutical firms. Its state‑of‑the‑art purification processes ensure consistent enantiomeric purity across batches.

   Sustainability & Growth Initiatives:

   • Adoption of green chemistry principles across all production stages
   • Collaboration with a leading Japanese university on catalytic hydrogenation
   • Expansion of its global logistics network to improve delivery times

9. Finetech Industry Limited (China)

   Headquarters: Shanghai, China
   Key Offering: Cost‑effective (R)-1‑Aminoindane, large‑scale production for generics

   Finetech’s competitive pricing and rapid turnaround have attracted a growing portfolio of generic manufacturers. Its integrated supply chain model reduces lead times and mitigates raw material volatility.

   Sustainability & Growth Initiatives:

   • Implementation of a closed‑loop solvent recovery system
   • Collaboration with an Indian CMO to expand capacity in South Asia
   • Investment in digital traceability for end‑to‑end supply chain transparency

10. Symone Chemicals (India)

    Headquarters: Bangalore, India
    Key Offering: Research‑grade (R)-1‑Aminoindane, custom synthesis for emerging markets

    Symone’s focus on emerging markets has positioned it as a key partner for Indian and Southeast Asian pharmaceutical companies. Its flexible production model accommodates diverse client needs, from small‑scale research to large‑volume API production.

    Sustainability & Growth Initiatives:

    • Adoption of renewable energy sources for plant operations
    • Collaboration with a national research institute on green catalytic processes
    • Expansion of its distribution network across the Indian subcontinent

Download FREE Sample Report

Get Full Report

Market Outlook

The trajectory of the (R)-1‑Aminoindane market reflects a confluence of factors that reinforce its position as a cornerstone for CNS drug development. The sustained increase in neurodegenerative disease prevalence, coupled with an expanding pipeline of MAO‑B inhibitors, keeps demand for high‑purity intermediates robust. Moreover, the shift toward precision medicine amplifies the need for stereochemically pure building blocks, ensuring that supply chains remain a strategic priority for pharmaceutical manufacturers.

Future Trends

• Continued adoption of biocatalytic resolution, lowering energy consumption and enhancing enantiomeric excess.
• Integration of digital twins and AI‑driven process control to accelerate scale‑up and reduce batch variability.
• Emergence of region‑specific regulatory frameworks that incentivize green chemistry, driving investment in sustainable production methods.
• Expansion into non‑neurocentric therapeutic areas, such as oncology and metabolic disorders, where chiral intermediates offer distinct therapeutic advantages.